×
About 16,133 results

ALLMedicine™ Irritable Bowel Syndrome Center

Research & Reviews  4,546 results

Self Administered Cognitive Behavior Therapy for Irritable Bowel Syndrome
https://clinicaltrials.gov/ct2/show/NCT00738920

Aug 5th, 2022 - Irritable bowel syndrome (IBS) is a chronic, prevalent, often disabling, GI disorder for which there is no reliable and satisfactory medical option for its full range of symptoms (abdominal pain, bowel dysfunction). An accumulating body of evidenc...

Predictive Value of Hydrogen/Methane Lactose Breath Testing on the Therapeutic Effect of Lactose-free Diet in Moderate to Severe ROME IV IBS.
https://clinicaltrials.gov/ct2/show/NCT04974593

Aug 4th, 2022 - Lactose intolerance (LI) results from lactose malabsorption (LM) secondary to insufficient hydrolysis of the disaccharide lactose into galactose and glucose (Misselwitz 2019). The undigested lactose will eventually reach the colon, resulting in fe...

Efficacy of a Low FODMAP Diet in the Absence of Lactose Malabsorption in Moderate to Severe ROME IV IBS.
https://clinicaltrials.gov/ct2/show/NCT05120752

Aug 4th, 2022 - Irritable bowel syndrome (IBS) is a frequently encountered disorder. According to the Rome IV criteria, it is characterized by abdominal pain associated with a change in stool frequency or con-sistency, or with symptomatic improvement by defecatio...

Colonoscopic Probiotics Infusion for Functional Gastrointestinal Disease
https://clinicaltrials.gov/ct2/show/NCT05366335

Aug 4th, 2022 - The purpose of this project is to study the the efficacy and safety of probiotics implantation through infusion during colonoscopy in the treatment of functional constipation and irritable bowel syndrome. The study is a single-center, prospective,...

Bifico relieves irritable bowel syndrome by regulating gut microbiota dysbiosis and inf...
https://doi.org/10.1007/s00394-022-02958-0
European Journal of Nutrition; Zhou Y, Zhang F et. al.

Aug 3rd, 2022 - Gut microbiota dysbiosis, a core pathophysiology of irritable bowel syndrome (IBS), is closely related to immunological and metabolic functions. Gut microbiota-based therapeutics have been recently explored in several studies. Bifico is a probioti...

see more →

Guidelines  14 results

AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Sy...
https://doi.org/10.1053/j.gastro.2022.04.016
Gastroenterology Chang L, Sultan S et. al.

Jun 24th, 2022 - Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction associated with significant disease burden. This American Gastroenterological Association guideline is intended to support practitioners in decisions about the use of med...

AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Sy...
https://doi.org/10.1053/j.gastro.2022.04.017
Gastroenterology Lembo A, Sultan S et. al.

Jun 24th, 2022 - Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder associated with significant disease burden. This American Gastroenterological Association Guideline is intended to support practitioners in decisions about the use of ...

AGA Clinical Practice Update on the Role of Diet in Irritable Bowel Syndrome: Expert Re...
https://doi.org/10.1053/j.gastro.2021.12.248
Gastroenterology Chey WD, Hashash JG et. al.

Mar 27th, 2022 - Irritable bowel syndrome (IBS) is a commonly diagnosed gastrointestinal disorder that can have a substantial impact on quality of life. Most patients with IBS associate their gastrointestinal symptoms with eating food. Mounting evidence supports d...

British Society of Gastroenterology guidelines on the management of irritable bowel syn...
https://doi.org/10.1136/gutjnl-2021-324598
Gut Vasant DH, Paine PA et. al.

Apr 28th, 2021 - Irritable bowel syndrome (IBS) remains one of the most common gastrointestinal disorders seen by clinicians in both primary and secondary care. Since publication of the last British Society of Gastroenterology (BSG) guideline in 2007, substantial ...

AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review.
https://doi.org/10.1053/j.gastro.2020.06.090
Gastroenterology Quigley EM, Murray JA et. al.

Jul 18th, 2020 - Thanks to ready access to hydrogen breath testing, small intestinal bacterial overgrowth is now commonly diagnosed among individuals presenting with a variety of gastrointestinal and even non-gastrointestinal complaints and is increasingly implica...

see more →

Drugs  253 results see all →

Clinicaltrials.gov  828 results

Self Administered Cognitive Behavior Therapy for Irritable Bowel Syndrome
https://clinicaltrials.gov/ct2/show/NCT00738920

Aug 5th, 2022 - Irritable bowel syndrome (IBS) is a chronic, prevalent, often disabling, GI disorder for which there is no reliable and satisfactory medical option for its full range of symptoms (abdominal pain, bowel dysfunction). An accumulating body of evidenc...

Predictive Value of Hydrogen/Methane Lactose Breath Testing on the Therapeutic Effect of Lactose-free Diet in Moderate to Severe ROME IV IBS.
https://clinicaltrials.gov/ct2/show/NCT04974593

Aug 4th, 2022 - Lactose intolerance (LI) results from lactose malabsorption (LM) secondary to insufficient hydrolysis of the disaccharide lactose into galactose and glucose (Misselwitz 2019). The undigested lactose will eventually reach the colon, resulting in fe...

Colonoscopic Probiotics Infusion for Functional Gastrointestinal Disease
https://clinicaltrials.gov/ct2/show/NCT05366335

Aug 4th, 2022 - The purpose of this project is to study the the efficacy and safety of probiotics implantation through infusion during colonoscopy in the treatment of functional constipation and irritable bowel syndrome. The study is a single-center, prospective,...

Efficacy of a Low FODMAP Diet in the Absence of Lactose Malabsorption in Moderate to Severe ROME IV IBS.
https://clinicaltrials.gov/ct2/show/NCT05120752

Aug 4th, 2022 - Irritable bowel syndrome (IBS) is a frequently encountered disorder. According to the Rome IV criteria, it is characterized by abdominal pain associated with a change in stool frequency or con-sistency, or with symptomatic improvement by defecatio...

Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)
https://clinicaltrials.gov/ct2/show/NCT04026113

Aug 2nd, 2022 - The objective of LIN-MD-64 is to evaluate the safety and efficacy of 12 weeks of linaclotide therapy (72 μg daily) in comparison with placebo in pediatric participants, 6 to 17 years of age, who fulfill modified Rome III Criteria for Child/Adolesc...

see more →

News  759 results

Jury Out on Synbiotics for Kids With GI Disorders
https://www.medscape.com/viewarticle/978815

Aug 8th, 2022 - There is insufficient evidence to recommend for or against the use of synbiotics to prevent or treat common gastrointestinal (GI) disorders in infants and children. That’s the conclusion of a position paper from the European Society for Pediatric ...

Commentary: Treatments for IBS, August 2022
https://www.mdedge.com/clinicianreviews/article/256640/ibd-intestinal-disorders/commentary-treatments-ibs-august-2022
Marita Kametas, MSN, FNP-BC, CMSRN, COCN

Jul 30th, 2022 - Marita Kametas, MSN, FNP-BC, CMSRN, COCN The study by El-Sahy and colleagues highlights the novel role of fecal microbiota transplant (FMT) in the treatment of irritable bowel syndrome (IBS). The safety and efficacy of this treatment was durable a.

Meta-analysis evaluates probiotic vs drug intervention in IBS
https://www.mdedge.com/clinicianreviews/article/256563/ibd-intestinal-disorders/meta-analysis-evaluates-probiotic-vs-drug

Jul 27th, 2022 - Key clinical point: Both probiotic and drug interventions decreased the persistence of irritable bowel syndrome (IBS) symptoms and abdominal pain scores compared with placebo in patients with IBS. Major finding: Compared with placebo, both probiot.

Fecal microbiota transplantation shows promise in patients with refractory IBS
https://www.mdedge.com/clinicianreviews/article/256562/ibd-intestinal-disorders/fecal-microbiota-transplantation-shows

Jul 27th, 2022 - Key clinical point: Fecal microbiota transplantation (FMT) reduced disease severity, improved microbiome α-diversity, and demonstrated a favorable safety profile in patients with refractory irritable bowel syndrome (IBS). Major finding: The IBS se.

Irritable bowel syndrome severely hampers work and daily living activities
https://www.mdedge.com/clinicianreviews/article/256561/ibd-intestinal-disorders/irritable-bowel-syndrome-severely-hampers

Jul 27th, 2022 - Key clinical point: Patients with irritable bowel syndrome (IBS) report a substantial impact of IBS on their abilities to work and perform daily activities. Major finding: Overall, 10.

see more →

Patient Education  53 results see all →